Gensight Biologics SA

SIGHT

Company Profile

  • Business description

    Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology, where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

  • Contact

    74, rue du Faubourg Saint-Antoine
    Paris75012
    FRA

    T: +33 176217220

    https://www.gensight-biologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.
stocks

Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand

We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks

Ahead of earnings, is Netflix a buy, a sell, or fairly valued?

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,226.7045.900.50%
CAC 408,258.9454.18-0.65%
DAX 4025,297.1355.26-0.22%
Dow JONES (US)49,415.4926.95-0.05%
FTSE 10010,235.293.65-0.04%
HKSE26,844.9678.66-0.29%
NASDAQ23,548.4018.380.08%
Nikkei 22553,936.17174.33-0.32%
NZX 50 Index13,718.1058.310.43%
S&P 5006,950.175.700.08%
S&P/ASX 2008,903.9048.100.54%
SSE Composite Index4,101.9110.69-0.26%

Market Movers